Published: Feb 16, 2021
~ Accurate rapid antigen tests for point of care with results in 10 minutes~
GREENVILLE, SC Feb 16, 2020 – According to a recent analysis conducted by the Harvard Global Health Institute and Brown University School of Public Health for NPR, 4.4 million tests are needed in the U.S. every day to reach a basic level of proactive testing.(1) Demand still exceeds supply for COVID-19 testing, and rapid antigen tests are a solution to expand testing capacity while providing the fastest turnaround of results. To help deliver COVID-19 testing solutions, Vessel Medical, a provider of medical workflow solutions, supplies, and equipment, is now offering CareStart™ rapid antigen testing. These tests are to be used as a point of care solution for medical professionals to provide to patients suspected of a COVID-19 infection.
“The CareStart™ rapid antigen tests are great for healthcare professionals in need of expanding their testing capacity and to add as another monitoring tool along with standard COVID-19 PCR tests,” stated Kevin Murdock, founder of Vessel Medical. “There are a few reasons why these tests are an ideal assay to monitor large amounts of patients in conjunction with PCR tests: First, because the specimen collection method required is minimally invasive, also the results are delivered in just 10 minutes, and they’re some of the most accurate rapid tests available.”
With an emergency use authorization (EUA) granted by the FDA, CareStart™ rapid antigen tests are lateral flow assays that identify acute infection in symptomatic patients. With 88.4% sensitivity and 100% specificity, they are among the most accurate rapid tests available. As it detects the Sars CoV-2 nucleocapsid protein antigen, the test is believed to also detect any new or emerging COVID-19 variants.
More about CareStart™ Antigen Tests:
- Deliver rapid results in 10 minutes
- Lateral flow assays
- Conducted by minimally invasive nasopharyngeal swab specimen collection
- Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver*, Certificate of Compliance, or Certificate of Accreditation
- Detect SARS-CoV-2 nucleocapsid protein antigen
- Identify acute infection in symptomatic patients with 88.4% sensitivity and 100% specificity
- Designated as a CLIA waived test
For more information, please call 1-888-714-5942 or click the following link: https://bit.ly/3qt2PdU